Neurological Disease History
c. 1000 BCE, Ayurvedic text describing Kampavata, ancient India
The condition now known as Parkinson's disease has been observed and described across many cultures and centuries, long before it received its modern name. Ancient Indian, Chinese, and Egyptian texts all contain passages that historians have interpreted as early descriptions of its characteristic features. The formal clinical identification of the disease as a distinct entity came in the early nineteenth century and launched a century of increasingly precise neurological investigation.
Historical Narrative
References to what may be Parkinson's disease appear in Ayurvedic Indian medical texts dating to around 1000 BCE, where a condition called 'Kampavata' — combining words for trembling and a disorder of bodily wind — was described and treated with preparations derived from the Mucuna pruriens plant, a legume that contains a naturally occurring precursor to dopamine. Chinese medical texts from the Han dynasty also described trembling palsy with postural changes in elderly individuals. The Edwin Smith Papyrus and other Egyptian medical writings contain passages that some historians have interpreted as references to trembling associated with advancing age.
In the Western tradition, Galen described what he called 'paralysis agitans,' or shaking palsy, distinguishing between tremors that occurred at rest and those that occurred during movement, a clinical distinction that would remain important in later centuries. Medieval European physicians generally subsumed trembling conditions under broader categories of palsy and attributed them to cooling and drying of the nervous spirits that were thought to animate the body.
The decisive moment in the history of the disease came in 1817 when James Parkinson, a London surgeon and political activist, published a sixty-six-page monograph titled 'An Essay on the Shaking Palsy.' Working from observations of only six individuals — some of whom he had merely watched on the streets of London — Parkinson provided a careful clinical description of the condition and argued, presciently, that its origin lay somewhere in the medulla oblongata. Despite the modesty of his evidence base, the essay was a milestone in systematic clinical observation.
Parkinson's essay was largely ignored for decades until Jean-Martin Charcot at the Salpêtrière hospital in Paris took up the subject in the 1860s and 1870s. Charcot refined the description considerably, distinguishing it clearly from multiple sclerosis and other trembling conditions, and proposed that the condition be named in honor of James Parkinson. Charcot also experimented with belladonna alkaloids derived from plants and with hyoscine as potential treatments, representing the first pharmacological approach to the disease.
The neurological basis of the disease was pushed forward dramatically in 1919 when the Russian-born French neurologist Konstantin Tretiakoff identified consistent degeneration in a region of the brainstem called the substantia nigra in patients who had died with the condition, linking the disease to a specific anatomical structure. The discovery that this region was connected to the body's movement control systems began to shift understanding toward biochemical mechanisms. The subsequent decades saw researchers increasingly focus on the specific chemical systems operating within the substantia nigra, work that would eventually culminate in one of the twentieth century's most celebrated neurological discoveries regarding neurotransmitter chemistry.
Key Historical Figures
Historical narrative only — this page describes how Parkinson's Disease was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.